Founded by Dr. Michael Abramoff, Digital Diagnostics has developed a biomarker-based approach to build an autonomous AI platform that removes the diagnostic burden of common diseases from specialists. Its flagship product, IDx-DR, has been FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema. The company is working closely with patient advocacy groups, federal regulators, and other stakeholders to enable the continued adoption of autonomous AI and democratize healthcare. Digital Diagnostics is paving the way for automated diagnosis to become a new standard of care that will significantly improve patient outcomes.